close

VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. The company offers MUSE, a minimally invasive therapy for erectile dysfunction. It develops drug candidates that address the need of obesity, diabetes, and sexual health markets. The company's late-stage clinical products, which are under development, include Qnexa that is in phase 3 clinical trials for obesity and completed phase 2 clinical trials for diabetes; Avanafil, which is in phase 3 studies to treat erectile dysfunction; and Luramist, for which the phase 2 study is completed for the treatment of hypoactive sexual desire disorder in women. It has a development, licensing, and supply agreement with Tanabe Seiyaku Co., Ltd. for the development of Avanafil; and licensing agreements with Acrux and its subsidiary to develop and, if approved, commercialize Luramist and Evamist in the United States. The company was founded in 1991 and is headquartered in Mountain View, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	20.05
Volume	(mio) 3.36
Volume Avg	(mio) 5.7
52 Week High	25.14
52 Week Low	6.00
PE	N/A
PE (group average)	39
EPS Year	-0.55
EPS change Q/Q	-50%
EPS change Q/Q Yr ago	-47.83%
EPS change Q/Q next Q est	-1100%
EPS change Y/Y	-25.71%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	-0.01
EPS next Y est	0.51
Divident Annual	0.00
Dividend Yield	0%